On Thursday, the World Health Organization (WHO) announced its support Weight loss drugs Adults all over the world.
The organization plans to handle GLP-1s like Wegovy and Zepbound Adult obesity As part of a change in dealing with the global obesity epidemic, as reported by Reuters.
In the memo, the agency summarized strategies to improve access to medicines in low- and middle-income countries, Reuters summed up.
“Oatzempic” Diet Weight Loss Drink: Does it work? Is it safe?
More than billions of people are obese worldwide, with about 70% of these individuals living in low- and middle-income countries, according to WHO data.
WHO has announced plans to support GLP-1 to deal with the global obesity epidemic. (istock)
The proven effectiveness of weight loss drugs has led individuals, particularly in other high-income countries such as the US and the UK and Germany, looking for GLP-1 solutions.
Visit for more lifestyle articles foxnews.com/lifestyle
However, as drugs can be priced at more than $1,000 a month, cost can be a factor, Reuters noted.
The proven effectiveness of weight loss drugs has led individuals, particularly in other high-income countries such as the US and the UK and Germany, looking for GLP-1 solutions. (Michael Siluk/UCG/Universal Images Group Getty Images)
In a statement, a WHO spokesman wrote that the agency is working on “a set of new recommendations on obesity prevention, care and treatment.” Children, young people And adults.
Click here to sign up for our Lifestyle Newsletter
The agency said it expects drug recommendations to be finalized by August or September 2025.
Guidance also includes “How and When”. Medicine Class The WHO may be integrated as one component of a chronic care model, including both clinical and lifestyle interventions.
In a statement, a WHO spokesman wrote that agents are working on “a set of new recommendations on obesity prevention, care and treatment” among different age groups. (Reuters/Dennis Balib House/File Photo)
WHO experts are also planning to meet next week to decide whether GLP-1 drugs should be included on the institution’s essential drug list to treat both obesity and type 2 diabetes.
Click here to get the Fox News app
It is also reported that the agency is looking for it Long-term research About the cost-effectiveness of “all settings” and income status for these drugs.
